HUTCHMED (China) Limited ( (HK:0013) ) has shared an update.
HUTCHMED (China) Limited announced an update regarding the timing of the dispatch of a circular related to the proposed disposal of a 45% equity interest in Shanghai Hutchison Pharmaceuticals Limited. The dispatch, initially expected by February 28, 2025, is now anticipated by March 31, 2025, due to additional time required for the designation process by GP Health Service Capital. The completion of this proposed disposal remains subject to the satisfaction of all conditions under the agreements, and shareholders are advised to exercise caution.
More about HUTCHMED (China) Limited
HUTCHMED (China) Limited is an innovative, commercial-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies and immunotherapies for cancer and immunological diseases. The company has successfully marketed its first three medicines in China, with one also approved in the US, Europe, and Japan.
YTD Price Performance: 14.04%
Average Trading Volume: 52,451
Technical Sentiment Consensus Rating: Sell
Current Market Cap: £2.38B
See more insights into 0013 stock on TipRanks’ Stock Analysis page.